Vedolizumab
Vedolizumab induces remission in more than 30% of UC patients with chronic pouchitis
Vedolizumab more effectively induced remission compared with placebo in patients with chronic pouchitis following ileal pouch-anal anastomosis for ulcerative colitis, according to research in The New England Journal of Medicine.
Q&A: Head-to-head studies needed to differentiate mirikizumab from IBD competitors
Mirikizumab, a monoclonal antibody poised to become first-in-class treatment for ulcerative colitis, has the potential to transform treatment paradigms — if it can distinguish itself in an already saturated and competitive market.
Vedolizumab may help prevent lower GI acute GVHD after unrelated stem cell transplant
Vedolizumab showed greater efficacy than placebo when added to standard prophylaxis for prevention of lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, according to a study.
‘Why not combine them?’: Early dual biologic therapy may overcome limits in severe IBD
DENVER — Early data suggest combination therapy with biologics or advanced small-molecules may be safe and effective in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.
Healio Minute Podcast, Gastroenterology Edition: Top Headlines - Week of November 21, 2022
In this edition, best practice statements for celiac disease; older patients with IBD at risk for treatment failure with vedolizumab; Follow-up surveillance for post-colonoscopy CRC and more.
Ustekinumab, vedolizumab ‘seem perfectly safe’ during pregnancy in IBD patients
CHARLOTTE, N.C. — Exposure to ustekinumab and vedolizumab during pregnancy did not increase maternal and fetal complications, and researchers recommend continued use in pregnant mothers with inflammatory bowel disease.
Older patients with IBD at higher risk for treatment failure with vedolizumab
Older patients with inflammatory bowel disease receiving vedolizumab, particularly those with Crohn’s disease, faced higher risk of treatment failure compared with patients receiving tumor necrosis factor antagonists.
IBD patients should ‘not delay their infusion’ if stable with COVID-19 infection
Use of biologics did not worsen stable SARS-CoV-2 infection in patients with inflammatory bowel disease if given within 2 weeks of virus detection, according to research published in Clinical Gastroenterology and Hepatology.
Hispanic patients with IBD at increased risk for hospitalization, surgery
Hispanic patients treated with biologic agents for inflammatory bowel diseases face a greater risk for hospitalization, surgery and infections compared with non-Hispanic patients, according to a study in Clinical Gastroenterology and Hepatology.
Vedolizumab, ustekinumab best anti-TNF for infection risk in older adult IBD
SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age.